Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.